gray market retatrutide peptides blur drug and supplement distinctions, raising health risks Beyond the GLP-1RA weight loss

Most importantly, we will learn what they knew about the risks when they failed to warn of stomach paralysis and intestinal blockage

Esser, N., Legrand-Poels, S., Piette, J., Scheen, A

Verified Patient Ingrid from Illinois SHE IS AMAZING

In 2019, the REWIND trial found that in the 9901 patients with T2DM with and without previous CVD randomly assigned to a once-weekly 1.5 mg dulaglutide injection or placebo (median follow-up 5.4 years), three-point MACE occurred in 594 patients receiving dulaglutide (12.0%) and in 663 patients (13.4%) in the placebo group, which included a significant decrease in the rate of non-fatal stroke (Gerstein et al

Activity recording is turned off

View care model PATIENT EXPERIENCE See what patients are saying about their experience at Family Medical Doctors in New Port Richey